These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 33199386)

  • 21. Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead.
    Gumbo T; Makhene MK; Seddon JA
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S110-S115. PubMed ID: 27742642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development.
    Gumbo T; Srivastava S; Deshpande D; Pasipanodya JG; Berg A; Romero K; Hermann D; Hanna D
    J Antimicrob Chemother; 2023 Apr; 78(4):953-964. PubMed ID: 36794692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
    Pasipanodya JG; Nuermberger E; Romero K; Hanna D; Gumbo T
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S10-7. PubMed ID: 26224767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
    Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
    J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
    Diacon AH; Dawson R; von Groote-Bidlingmaier F; Symons G; Venter A; Donald PR; van Niekerk C; Everitt D; Hutchings J; Burger DA; Schall R; Mendel CM
    Am J Respir Crit Care Med; 2015 Apr; 191(8):943-53. PubMed ID: 25622149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
    Diacon AH; Dawson R; von Groote-Bidlingmaier F; Symons G; Venter A; Donald PR; van Niekerk C; Everitt D; Winter H; Becker P; Mendel CM; Spigelman MK
    Lancet; 2012 Sep; 380(9846):986-93. PubMed ID: 22828481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.
    Srivastava S; Deshpande D; Pasipanodya J; Nuermberger E; Swaminathan S; Gumbo T
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S102-S109. PubMed ID: 27742641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity against Mycobacterium tuberculosis of levofloxacin, moxifloxacin and UB-8902 in combination with clofazimine and pretomanid.
    López-Gavín A; Tudó G; Vergara A; Hurtado JC; Gonzalez-Martín J
    Int J Antimicrob Agents; 2015 Nov; 46(5):582-5. PubMed ID: 26421981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration.
    Gumbo T; Sherman CM; Deshpande D; Alffenaar JW; Srivastava S
    Int J Infect Dis; 2021 Mar; 104():680-684. PubMed ID: 33556616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
    Kadura S; King N; Nakhoul M; Zhu H; Theron G; Köser CU; Farhat M
    J Antimicrob Chemother; 2020 Aug; 75(8):2031-2043. PubMed ID: 32361756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The within-host population dynamics of Mycobacterium tuberculosis vary with treatment efficacy.
    Trauner A; Liu Q; Via LE; Liu X; Ruan X; Liang L; Shi H; Chen Y; Wang Z; Liang R; Zhang W; Wei W; Gao J; Sun G; Brites D; England K; Zhang G; Gagneux S; Barry CE; Gao Q
    Genome Biol; 2017 Apr; 18(1):71. PubMed ID: 28424085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model.
    Pieterman ED; Te Brake LHM; de Knegt GJ; van der Meijden A; Alffenaar JC; Bax HI; Aarnoutse RE; de Steenwinkel JEM
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthetic investigational new drugs for the treatment of tuberculosis.
    Kwon YS; Koh WJ
    Expert Opin Investig Drugs; 2016; 25(2):183-93. PubMed ID: 26576631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Not Available].
    Tiberi S; Buchanan R; Caminero JA; Centis R; Arbex MA; Salazar M; Potter J; Migliori GB
    Presse Med; 2017 Mar; 46(2 Pt 2):e41-e51. PubMed ID: 28256383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.
    Naidoo A; Naidoo K; McIlleron H; Essack S; Padayatchi N
    J Clin Pharmacol; 2017 Nov; 57(11):1369-1386. PubMed ID: 28741299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model.
    Liu Y; Pertinez H; Davies GR; Gillespie SH; Coates AR; Hu Y
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model.
    Silva A; Lee BY; Clemens DL; Kee T; Ding X; Ho CM; Horwitz MA
    Proc Natl Acad Sci U S A; 2016 Apr; 113(15):E2172-9. PubMed ID: 27035987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
    Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL
    J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time.
    Lee BY; Clemens DL; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    Nat Commun; 2017 Jan; 8():14183. PubMed ID: 28117835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.